PLUS1
2.28
-0.18 (-7.32%)
-0.18 (-7.32%)
Upgrade to Real-Time
Market Closed
Best deals to access real time data! |
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Canna Trader Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| CytoDyn Inc (QB) | CYDY | OTCMarkets | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| -0.18 | -7.32% | 2.28 | 16:00:02 |
| Close Price | Low Price | High Price | Open Price | Previous Close |
|---|---|---|---|---|
| 2.28 | 2.25 | 2.49 | 2.49 | 2.46 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 2.28 | 2.29 | 0.01 | 2 | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 3,475 | 4,129,343 | $ 2.3199 | $ 9,579,863 | 4,454,192 | 0.261 - 10.01 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:01:07 | formt | 100 | $ 2.2801 | USD |
CytoDyn (QB) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 1.30B | 569.32M | 302.11M | $ - | $ - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 23.36M | $ - | 0.00% | - | - |
CytoDyn (QB) News
| Date | Time | Source | News Article |
|---|---|---|---|
| 10/26/2020 | 19:55 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 10/26/2020 | 19:45 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 10/09/2020 | 08:32 | Edgar (US Regulatory) | Quarterly Report (10-q) |
| 10/02/2020 | 18:40 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 10/02/2020 | 18:28 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 10/02/2020 | 18:19 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 9/30/2020 | 17:25 | Edgar (US Regulatory) | Securities Registration: Employee Benefit Plan (s-8) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CYDY Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.82 | 3.09 | 2.25 | 2.67 | 3,202,932 | -0.54 | -19.15% |
| 1 Month | 3.38 | 3.87 | 2.25 | 2.98 | 3,393,093 | -1.10 | -32.54% |
| 3 Months | 5.07 | 5.36 | 2.25 | 3.63 | 4,326,520 | -2.79 | -55.03% |
| 6 Months | 3.28 | 10.01 | 2.25 | 4.36 | 6,171,284 | -1.00 | -30.49% |
| 1 Year | 0.326 | 10.01 | 0.261 | 3.29 | 5,284,721 | 1.95 | 599.39% |
| 3 Years | 0.565 | 10.01 | 0.0552 | 2.96 | 1,990,136 | 1.72 | 303.54% |
| 5 Years | 0.89 | 10.01 | 0.0552 | 2.81 | 1,285,929 | 1.39 | 156.18% |
CytoDyn (QB) Description
| CytoDyn Inc. is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Leronlimab is in a class of therapeutic monoclonal antibodies designed to address unmet medical needs in the areas of Human Immunodeficiency Virus (HIV), Cancer, and Immunology. |
